EndoForce™ Connector
Endovascular venous anastomosis for arteriovenous graft (AVG) implantation in hemodialysis access
Key Facts
About Phraxis
Phraxis is a private, commercial-stage medical device company that has developed and received FDA approval for the EndoForce™ Connector, a novel implant for creating endovascular venous anastomoses in hemodialysis access procedures. The technology replaces traditional surgical suturing with a transcatheter-deployed device, demonstrating a 92% cumulative patency rate in its pivotal trial, which surpasses the historical standard. Led by CEO and inventor Dr. Alex Yevzlin, the company is positioned to address significant clinical challenges in renal care by streamlining AVG creation and improving long-term outcomes for dialysis patients. Phraxis is now focused on the commercial rollout and adoption of its first product.
View full company profile